Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults…
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiologys Annual Scientific Session 2025
− New Data Follow Recent U.S. FDA Approval of AMVUTTRA® (vutrisiran) as…
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical…
Positron Corporation Secures Agreement for Three NeuSight PET-CT 64 Slice Scanners
Niagara Falls, NY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (OTC:…
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions
SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. today announced…
Lifetime Achievement Award Posthumously Bestowed Upon Dr. Vishakha Tripathi Ji for Her Outstanding Service to Humanity
NEW DELHI, Dec. 21, 2024 /PRNewswire/ -- Jagadguru Kripalu Parishat (JKP) announces…
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Phase 3 trial results published in European Journal of Heart Failure identify…
India shines at London Valves 2024: Meril’s groundbreaking leap in heart valve innovation ‘Myval Octapro THV’ showcased at GISE 2024 and PCR London Valves
VAPI, India, Nov. 27, 2024 /PRNewswire/ -- Meril Life Sciences, a leading…
Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label…
Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance
NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Fourth Frontier, a medical technology…